William J. Gradishar, MD, on Hormone-Sensitive Breast Cancer: Treatment Update

NCCN 2018 Annual Conference
Tweet this page

William J. Gradishar, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses recent evidence on the efficacy, safety, and utility of HER2-targeted treatments in the adjuvant setting for early-stage and advanced breast cancers.

Advertisement

Advertisement



Advertisement